Kadmon Holdings, Inc. (KDMN)
KDMN Stock Price Chart
|Net Income (ttm)||-94.88M|
|Trading Day||December 4|
|Day's Range||4.07 - 4.23|
|52-Week Range||2.44 - 5.26|
KDMN Stock News
The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.
Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
In times of market turbulence, cheap stocks offer a unique way to escape the broad moves up and down and instead benefit from big potential. The post 7 Cheap Stocks to Buy With Great Potentia...
The company reported positive results from a clinical trial for one of its most promising pipeline candidates.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
There are high chances of KD025 securing FDA approval in cGVHD indication.
No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.
Kadmon: Updates To Thesis, Pivotal cGVHD Data Impresses
Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.
Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?
Positive clinical trial results for the biopharmaceutical company's lead candidate, KD025, are driving investors' optimism.
Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary end...
Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares have lost a third of their value since my initial article.
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
Kadmon Holdings, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the trea... [Read more...]
|IPO Date |
Jul 27, 2016
Dr. Harlan W. Waksal
|Stock Exchange |
|Ticker Symbol |
In 2019, KDMN's revenue was $5.10 million, an increase of 264.97% compared to the previous year's $1.40 million. Losses were -$61.37 million, 13.1% more than in 2018.